The early impact of vaccination against SARS-CoV-2 in Region Stockholm, Sweden.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
03 05 2022
Historique:
received: 12 08 2021
revised: 21 03 2022
accepted: 23 03 2022
pubmed: 9 4 2022
medline: 28 4 2022
entrez: 8 4 2022
Statut: ppublish

Résumé

Vaccination against SARS-CoV-2 started in Region Stockholm, Sweden in December 2020 with those in long-term care facilities or receiving home care vaccinated first followed by those aged over 80 years. In this population-based, retrospective cohort study, we performed a Poisson regression to model the expected incidence of infections and deaths which we compared to the observed incidence and compared this to an unvaccinated control group of those aged 18-79 years. The aim of this study was to measure the early impact of the vaccination programme in Region Stockholm. Infections and deaths reduced substantially amongst the first two groups targeted for SARS-CoV-2 vaccination with an estimated total 3112 infections prevented, and 854 deaths prevented in these two groups from 4 weeks after the introduction of vaccination through to 2nd May 2021.

Identifiants

pubmed: 35393149
pii: S0264-410X(22)00372-3
doi: 10.1016/j.vaccine.2022.03.061
pmc: PMC8960184
pii:
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2823-2827

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Catherine Isitt (C)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden. Electronic address: catherine.isitt@regionstockholm.se.

Daniel Sjöholm (D)

Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden.

Maria-Pia Hergens (MP)

Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden; Department of Communicable Disease Control and Prevention, Stockholm County Council, Stockholm, Sweden.

Fredrik Granath (F)

Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden.

Pontus Nauclér (P)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Sweden. Electronic address: pontus.naucler@regionstockholm.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH